Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Table 3 The predictive impact of factors on efficacy

The impact factors of Objective response	Univariate analysis		Multivariate analysis
The impact factors of Objective response	P-value	OR (95%CI)	P-value	OR (95%CI)
Age	0.511
ECOG	0.812
Histology	0.952
FIGO stage	0.765
Neoadjuvant therapy	0.706
Residual tumor	0.296
Response status to platinum	0.036		0.017
Resistant VS. Refractory	0.033	3.694 (1.114–12.250)	0.014	5.241 (1.404–19.566)
Partially sensitive VS. Refractory	0.013	4.046 (1.339–12.227)	0.007	5.308 (1.591–17.713)
Baseline CA125	0.077		0.030
200–500 VS. ≤200	0.146	0.491 (0.188–1.281)	0.033	0.317 (0.110–0.911)
≥500 VS. ≤200	0.039	0.260 (0.072–0.934)	0.029	0.219 (0.056–0.875)

ECOG Eastern Cooperative Oncology Group, FIGO International federation of Gynecology and Obstetrics

ISSN: 1757-2215